January 8, 2018 / 12:11 PM / 11 days ago

BRIEF-Matinas BioPharma Achieves Statistical Endpoint For Success In Phase 2a Clinical Study Of Orally-Administered MAT2203

Jan 8 (Reuters) - Matinas Biopharma Holdings Inc:

* MATINAS BIOPHARMA ACHIEVES STATISTICAL ENDPOINT FOR SUCCESS IN PHASE 2A CLINICAL STUDY OF ORALLY-ADMINISTERED MAT2203 FOR THE TREATMENT OF CHRONIC REFRACTORY MUCOCUTANEOUS CANDIDIASIS

* MATINAS BIOPHARMA - ‍INVESTIGATORS FROM NATIONAL INSTITUTES OF HEALTH RELAYED POSITIVE DATA FROM THIRD PATIENT ENROLLED IN PHASE 2A STUDY OF MAT2203​

* MATINAS BIOPHARMA HOLDINGS INC - THE THIRD PATIENT MET PRIMARY ENDPOINT OF PHASE 2A STUDY WITH TREATMENT OF MAT2203​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below